Clinical trials
Systemic Inflammatory Response Syndrome clinical trials
Below are recruiting systemic inflammatory response syndrome clinical trials, each written for real people, not researchers. We’re tracking 38 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05670301Recruiting
Blood test study to profile inflammation biomarkers in diseases
This study measures blood “biomarkers” (signals in blood) to better understand inflammatory diseases, including autoimmune and autoinflammatory conditions. You may be asked to give blood samples now and possibly extra samples if needed for testing.
AntwerpAges Any age - NCT07527247RecruitingPhase 2
Testing a New Yellow Fever and Dengue Vaccine
This study tests a new vaccine designed to improve protection against yellow fever and dengue fever in healthy adults. Researchers want to see if this vaccine works better than existing ones and is safe.
SingaporeAges 21–59 - NCT07636733Recruiting
Vitamin D for Gum and Bone Health in Periodontal Disease
This study tests whether vitamin D supplements can reduce inflammation and improve healing in people with gum disease, ranging from mild gingivitis to advanced periodontitis. Researchers will compare how vitamin D affects different stages of gum disease.
RizeAges 18–70 - NCT07038447Enrolling by invitationPhase 1
KITE-363 for refractory autoimmune diseases
This trial tests a new cell therapy called KITE-363 for people with certain autoimmune diseases (lupus, lupus nephritis, systemic sclerosis, or idiopathic inflammatory myopathy) that haven't improved with standard treatments. It aims to see if this therapy can help control the disease.
Duarte, CaliforniaAges 18 years+ - NCT07305116RecruitingPhase 1
CAR T-cell therapy for autoimmune diseases
This trial tests a new immune therapy called CAR T-cells that target two proteins (CD19 and BCMA) to treat autoimmune diseases like lupus, nephrotic syndrome, and others. It is for people whose standard treatments have not worked well enough.
Hangzhou, ZhejiangAges 3 years+ - NCT07507201RecruitingEarly Phase 1
Car-T cells for autoimmune diseases like lupus
This trial tests whether specially-engineered immune cells (CAR-T cells) can help people with certain autoimmune diseases that haven't gotten better with standard treatments. The cells are designed to target and remove faulty B cells that are causing the immune system to attack the body.
Hangzhou, ZhejiangAges 3 years+ - NCT07586267RecruitingEarly Phase 1
CAR-T cell therapy for autoimmune blood diseases
This early-stage trial tests a new type of cell therapy (CAR-T cells) designed to treat severe autoimmune diseases where the immune system attacks the body's own organs. The therapy targets specific immune cells (B cells) that may be causing the disease. It may help patients who haven't improved with standard treatments or can't tolerate them.
Hangzhou, ZhejiangAges 3 years+ - NCT04561557RecruitingEarly Phase 1
Cell therapy for relapsing nervous system autoimmune diseases
This early-phase trial tests CT103A “CAR-T” cell therapy to treat certain relapsing or treatment-resistant autoimmune diseases that affect the nervous system. It aims to see whether the cells are safe and may help reduce disease activity when standard treatments haven’t controlled symptoms.
Wuhan, HubeiAges 18–75 - NCT06477653RecruitingPhase 2
Dupilumab for hypereosinophilic syndrome with ongoing symptoms
This trial tests if dupilumab, added to your current treatment, can help with remaining symptoms of hypereosinophilic syndrome (HES) like asthma, eczema, nasal polyps, or eosinophilic esophagitis. You may qualify if you're already on a biologic therapy that lowers eosinophils but still have bothersome symptoms.
Bethesda, MarylandAges 18–99 - NCT06375993Enrolling by invitationPhase 1
Prula-cel for autoimmune diseases: a phase 1 study
This trial tests a new treatment called prulacabtagene leucel (prula-cel), which is a type of immune cell therapy (CAR T-cells) for people with certain autoimmune diseases. It aims to see if it can reset the immune system and reduce disease activity in conditions like lupus, scleroderma, vasculitis, or myositis.
Redwood City, CaliforniaAges 18–80 - NCT07315087RecruitingPhase 1
CAR T-cell therapy for autoimmune diseases
This trial tests a special type of cell therapy (CAR T-cells) that targets two markers on immune cells, CD19 and BCMA, to calm overactive immune systems in people with certain autoimmune diseases. It's for those whose disease has not been controlled by standard treatments.
TianjinAges 18 years+ - NCT06733935RecruitingPhase 1/Phase 2
Study of NKX019 for immune diseases
This trial tests an investigational cell therapy called NKX019 for people with certain autoimmune diseases like scleroderma, myositis, vasculitis, or rheumatoid arthritis. It aims to see if NKX019 can help control the disease when standard treatments have not worked well enough.
Orange, CaliforniaAges 18–75 - NCT06933173Recruiting
Mind-body therapy for Long COVID and ME/CFS
This trial tests whether a specific mind-body program can help people with Long COVID or ME/CFS feel better. It compares the program to standard care to see if it improves symptoms like fatigue and brain fog.
Calgary, AlbertaAges 18 years+ - NCT07037472Recruiting
Imaging calcium deposits in dermatomyositis patients
This study uses a special imaging technique (photoacoustic/ultrasound) to look at calcium deposits under the skin in people with dermatomyositis. It aims to find patterns that help doctors understand the condition and track how well treatments work.
BeijingAges 18–80
Hear when a new Systemic Inflammatory Response Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for systemic inflammatory response syndrome?
- Yes. Clin2 currently lists 38 recruiting systemic inflammatory response syndrome studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a systemic inflammatory response syndrome trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a systemic inflammatory response syndrome trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.